Reed has over 20 years of experience in the diagnostic and pharmaceutical industries commercializing innovative products and solutions that are at the leading edge of technology. Reed sees the rapidly growing field of combining precision NGS-based diagnostics, including liquid biopsy, with targeted therapeutics and immunotherapies as one of the keystone opportunities of making cancer a manageable condition. The knowledge we have of the genome is growing rapidly, and leveraging these insights in the clinic is transforming the cancer care landscape. Reed has a degree in biochemistry from the University of Michigan.
Richard is the CCO at Proteome Sciences and has over 30 years’ experience working in the proteomics and biotechnology sectors. Since joining Proteome Sciences in 2017 he has focused on leading the Company’s marketing and commercialisation strategy to offer clients a flexible, high quality service in our CRO business.
Dr. Ginette Serrero is Chief Executive Officer of Precision Antibody, a custom antibody development company, expert in the design, development, characterization and production of monoclonal antibodies for the treatment and diagnosis of human diseases. She draws on biotech management and research expertise in Oncology and biomarker discovery to guide the company's strategy in both the service division and R&D department for the development of biological targeted therapies with companion tissue and serum diagnostics for breast cancer. Her laboratory discovered Progranulin (GP88) as a marker of recurrence, drug resistance and tumor aggressiveness for several cancers including breast and lung cancer. This led to the development of two companion diagnostics that have been clinically validated for disease prognosis and monitoring of breast and lung cancer patients. She is a trained Biochemist with expertise in target discovery, Pharmaceutical Sciences and Oncology. She is Adjunct Professor at the University of Maryland Greenebaum Comprehensive Cancer Center.
She is inventor on several worldwide patents for targets in Oncology and authored 100 peer-reviewed scientific publications and reviews.
